Study Objectives. The aim of this study is to investigate the correlation between serum high-sensitivity C-reactive protein (hs-CRP) and other clinical tools including high-resolution computed tomography (HRCT) in patients with stable non-CF bronchiectasis. Design. A within-subject correlational study of a group of patients with stable non-CF bronchiectasis, who were recruited from our outpatient clinic, was done over a two-year period. Measurements. Sixty-nine stable non-CF bronchiectasis patients were evaluated in terms of hs-CRP, 6-minute walk test, pulmonary function tests, and HRCT. Results. Circulating hs-CRP levels were significantly correlated with HRCT scores ( , , ) and resting oxygenation saturation ( , ). HRCT severity scores significantly increased in patients with hs-CRP level of 4.26？mg/L or higher (mean ± SD ) compared to those with hs-CRP level less than 4.26？mg/L ( , ). Oxygenation saturation at rest was lower in those with hs-CRP level of 4.26？mg/L or higher ( ) compared to those with hs-CRP level less than 4.26？mg/L ( , ). Conclusion. There was a good correlation between serum hs-CRP and HRCT scores in the patients with stable non-CF bronchiectasis. 1. Introduction Despite improvements in childhood immunization and tuberculosis control, bronchiectasis remains a significant clinical issue worldwide [1, 2]. It is a chronic, debilitating lung disease characterized by irreversible dilatation of the bronchi from airway remodeling due to chronic airway inflammation and infection. Underlying etiologies include autoimmune diseases, severe infections, genetic abnormalities, and acquired disorders; however, its pathogenesis and progression remain poorly understood [1–5]. Exacerbations occur at rates of 1.5–6.5 per patient per year [6, 7] and are associated with an increased risk of admission and readmission to hospitals and high healthcare costs [8]. High-resolution computed tomography (HRCT) is a proven, reliable, and noninvasive method for assessing bronchiectasis [9]. It can accurately diagnose bronchiectasis and localize and describe areas of parenchymal abnormality. A link between morphological HRCT parameters and clinical functional correlation has been established [9–14]. However, concerns over radiation exposure and high cost limit its frequent use in stable bronchiectasis patients. Inflammation in bronchiectasis is characterized by persistence and intensity. Airway inflammation is neutrophil-predominant, and inflammatory profiles show increased levels of proinflammatory cytokines such as IL-1, IL-6, and TNF-α and low levels of
References
[1]
A. F. Barker, “Bronchiectasis,” The New England Journal of Medicine, vol. 346, no. 18, pp. 1383–1393, 2002.
[2]
K. W. Tsang and G. L. Tipoe, “Bronchiectasis: not an orphan disease in the East,” International Journal of Tuberculosis and Lung Disease, vol. 8, no. 6, pp. 691–702, 2004.
[3]
S. Fuschillo, A. De Felice, and G. Balzano, “Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms,” European Respiratory Journal, vol. 31, no. 2, pp. 396–406, 2008.
[4]
T. Keistinen, O. S？yn？j？kangas, T. Tuuponen, and S.-L. Kivel？, “Bronchiectasis: an orphan disease with a poorly-understood prognosis,” European Respiratory Journal, vol. 10, no. 12, pp. 2784–2787, 1997.
[5]
A. E. O'Donnell, “Bronchiectasis,” Chest, vol. 134, no. 4, pp. 815–823, 2008.
[6]
H. J. Roberts and R. Hubbard, “Trends in bronchiectasis mortality in England and Wales,” Respiratory Medicine, vol. 104, no. 7, pp. 981–985, 2010.
[7]
A. E. O'Donnell, A. F. Barker, J. S. Ilowite, and R. B. Fick, “Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I,” Chest, vol. 113, no. 5, pp. 1329–1334, 1998.
[8]
M. C. Pasteur, D. Bilton, and A. T. Hill, “British thoracic society guideline for non-CF bronchiectasis,” Thorax, vol. 65, supplement 1, pp. i1–i58, 2010.
[9]
G. C. Ooi, P. L. Khong, M. Chan-Yeung et al., “High-resolution CT quantification of bronchiectasis: clinical and functional correlation,” Radiology, vol. 225, no. 3, pp. 663–672, 2002.
[10]
H. R. Roberts, A. U. Wells, M. B. Rubens et al., “Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests,” Thorax, vol. 55, no. 3, pp. 198–204, 2000.
[11]
R. E. Sheehan, A. U. Wells, S. J. Copley et al., “A comparison of serial computed tomography and functional change in bronchiectasis,” European Respiratory Journal, vol. 20, no. 3, pp. 581–587, 2002.
[12]
D. B. Reiff, A. U. Wells, D. H. Carr, P. J. Cole, and D. M. Hansell, “CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types,” American Journal of Roentgenology, vol. 165, no. 2, pp. 261–267, 1995.
[13]
P. Grenier, M.-P. Cordeau, and C. Beigelman, “High-resolution computed tomography of the airways,” Journal of Thoracic Imaging, vol. 8, no. 3, pp. 213–229, 1993.
[14]
G. McGuinness and D. P. Naidich, “Bronchiectasis: CT/clinical correlations,” Seminars in Ultrasound CT and MRI, vol. 16, no. 5, pp. 395–419, 1995.
[15]
B. Schaaf, A. Wieghorst, S.-P. Aries, K. Dalhoff, and J. Braun, “Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis,” Respiration, vol. 67, no. 1, pp. 52–59, 2000.
[16]
J. C. W. Mak, S. P. Ho, R. Y. H. Leung et al., “Elevated levels of transforming growth factor-β1 in serum of patients with stable bronchiectasis,” Respiratory Medicine, vol. 99, no. 10, pp. 1223–1228, 2005.
[17]
C. B. Wilson, P. W. Jones, C. J. O'Leary et al., “Systemic markers of inflammation in stable bronchiectasis,” European Respiratory Journal, vol. 12, no. 4, pp. 820–824, 1998.
[18]
M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003.
[19]
P. M. Ridker, “High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease,” Circulation, vol. 103, no. 13, pp. 1813–1818, 2001.
[20]
M. J. Kaplan, “Management of cardiovascular disease risk in chronic inflammatory disorders,” Nature Reviews, vol. 5, no. 4, pp. 208–217, 2009.
[21]
B. M. Everett, T. Kurth, J. E. Buring, and P. M. Ridker, “The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2235–2242, 2006.
[22]
P. M. Ridker, M. J. Stampfer, and N. Rifai, “Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease,” Journal of the American Medical Association, vol. 285, no. 19, pp. 2481–2485, 2001.
[23]
M. Cesari, B. W. J. H. Penninx, A. B. Newman et al., “Inflammatory markers and onset of cardiovascular events: results from the health ABC study,” Circulation, vol. 108, no. 19, pp. 2317–2322, 2003.
[24]
E. T. H. Yeh and J. T. Willerson, “Coming of age of C-reactive protein: using inflammation markers in cardiology,” Circulation, vol. 107, no. 3, pp. 370–372, 2003.
[25]
A. S. Brody, J. S. Klein, P. L. Molina, J. Quan, J. A. Bean, and R. W. Wilmott, “High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests,” Journal of Pediatrics, vol. 145, no. 1, pp. 32–38, 2004.
[26]
“ATS statement: guidelines for the six-minute walk test,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 1, pp. 111–117, 2002.
[27]
M. R. Loebinger, A. U. Wells, D. M. Hansell et al., “Mortality in bronchiectasis: a long-term study assessing the factors influencing survival,” European Respiratory Journal, vol. 34, no. 4, pp. 843–849, 2009.
[28]
Z. P. Onen, B. Eris Gulbay, E. Sen et al., “Analysis of the factors related to mortality in patients with bronchiectasis,” Respiratory Medicine, vol. 101, no. 7, pp. 1390–1397, 2007.
[29]
B. Weinhold and U. Rüther, “Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene,” Biochemical Journal, vol. 327, no. 2, pp. 425–429, 1997.
[30]
N. Yoshida, S. Ikemoto, K. Narita et al., “Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma,” British Journal of Cancer, vol. 86, no. 9, pp. 1396–1400, 2002.
[31]
T. D. Spector, D. J. Hart, D. Nandra et al., “Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease,” Arthritis and Rheumatism, vol. 40, no. 4, pp. 723–727, 1997.
[32]
A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001.
[33]
J. P. De Torres, V. Pinto-Plata, C. Casanova et al., “C-reactive protein levels and survival in patients with moderate to very severe COPD,” Chest, vol. 133, no. 6, pp. 1336–1343, 2008.
[34]
M. Takemura, H. Matsumoto, A. Niimi et al., “High sensitivity C-reactive protein in asthma,” European Respiratory Journal, vol. 27, no. 5, pp. 908–912, 2006.
[35]
M. Gaga, A. M. Bentley, M. Humbert et al., “Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis,” Thorax, vol. 53, no. 8, pp. 685–691, 1998.
[36]
A. L. Lee, B. M. Button, S. Ellis et al., “Clinical determinants of the 6-Minute Walk Test in bronchiectasis,” Respiratory Medicine, vol. 103, no. 5, pp. 780–785, 2009.
[37]
E. A. Edwards, I. Narang, I. Li, D. M. Hansell, M. Rosenthal, and A. Bush, “HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis,” European Respiratory Journal, vol. 24, no. 4, pp. 538–544, 2004.
[38]
M. Dupont, A. Gacouin, H. Lena et al., “Survival of patients with bronchiectasis after the first ICU stay for respiratory failure,” Chest, vol. 125, no. 5, pp. 1815–1820, 2004.
[39]
C. Kroegel, M. Schüler, M. F？rster, R. Braun, and P. R. Grahmann, “Evidence for eosinophil activation in bronchiectasis unrelated to cystic fibrosis and bronchopulmonary aspergillosis: discrepancy between blood eosinophil counts and serum eosinophil cationic protein levels,” Thorax, vol. 53, no. 6, pp. 498–500, 1998.
[40]
F. Santamaria, S. Montella, M. Pifferi et al., “A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy,” Respiration, vol. 77, no. 2, pp. 160–165, 2009.
[41]
P. Cole and R. Wilson, “Host-microbial interrelationships in respiratory infection,” Chest, vol. 95, no. 3, 1989.
[42]
K. W. Tsang, K. C. Tan, P. L. Ho et al., “Inhaled fluticasone in bronchiectasis: a 12 month study,” Thorax, vol. 60, no. 3, pp. 239–243, 2005.
